6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl)amino)hexanal | 1129547-78-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl)amino)hexanal
• 英文别名: 6-[4-[(8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl]-N-methylanilino]hexanal
• CAS: 1129547-78-9
• 化学式: C₃₄H₄₃NO₃
• 分子量: 513.72
• InChiKey: BJQITMRJFUZTCZ-FMHBTXFXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  38
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl)amino)hexanal 、 (S)-10-((dimethylamino)methyl)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl piperazine-1-carboxylate 在 溶剂黄146 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 以143 mg的产率得到(S)-10-((dimethylamino)methyl)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl)amino)hexyl)piperazine-1-carboxylate
  参考文献：
  名称：

  WO2024073626A2

  摘要：

  公开号：
• 作为产物：
  描述：

  17β-hydroxy-11β-{4-[5-(1,3-dioxol-2-yl)-N-methylpentylamino]-phenyl}-17α-(1-propinyl)-estra-4,9-dien-3-one 在 盐酸 、 水 作用下， 以 甲醇 为溶剂， 反应 72.0h， 以53%的产率得到6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl)amino)hexanal
  参考文献：
  名称：

  Syntheses and Antigestagenic Activity of Mifepristone Derivatives

  摘要：

  A series of mifepristone derivatives with different "linker groups" in position 4' of the phenyl ring in the 11 beta-position of the steroid scaffold (2-41) have been synthesized. Their antigestagenic activites were determined in a cell-based assay (alkali phosphatase assay in T47-D breast cancer cells) and compared with that of the parent compound mifepristone. SAR and QSAR studies reveal the influence of both lipophilicity and partial charge based van der Waals surface area descriptors on biological activity. Within the series of compounds described in this study, three n-mifepristone derivatives are identified with considerably high antigestagenic activity. These compounds are regarded as useful starting materials for the synthesis of either physiologically stable or cleavable progesterone receptor-binding conjugates for therapeutic or diagnostic purposes.

  DOI：

  10.1021/jm800985z

文献信息

• WO2024097775A1
  申请人：——

  公开号：——

  公开（公告）日：——
• Syntheses and Antigestagenic Activity of Mifepristone Derivatives
  作者：Claudia Hödl、Katrin Raunegger、Rainer Strommer、Gerhard F. Ecker、Olaf Kunert、Sonja Sturm、Christoph Seger、Ernst Haslinger、Rudolf Steiner、Wolfgang S. L. Strauss、Hans-Wolfgang Schramm

  DOI：10.1021/jm800985z

  日期：2009.3.12

  A series of mifepristone derivatives with different "linker groups" in position 4' of the phenyl ring in the 11 beta-position of the steroid scaffold (2-41) have been synthesized. Their antigestagenic activites were determined in a cell-based assay (alkali phosphatase assay in T47-D breast cancer cells) and compared with that of the parent compound mifepristone. SAR and QSAR studies reveal the influence of both lipophilicity and partial charge based van der Waals surface area descriptors on biological activity. Within the series of compounds described in this study, three n-mifepristone derivatives are identified with considerably high antigestagenic activity. These compounds are regarded as useful starting materials for the synthesis of either physiologically stable or cleavable progesterone receptor-binding conjugates for therapeutic or diagnostic purposes.
• WO2024073626A2
  申请人：——

  公开号：——

  公开（公告）日：——